Mechanism of action of myosin X, a membrane-associated molecular motor

Mihály Kovács*, Fei Wang and James R. Sellers

Laboratory of Molecular Physiology, National Heart, Lung and Blood Institute, Bethesda, MD 20892-1762

*Correspondence should be addressed to Mihály Kovács, Laboratory of Molecular Physiology, National Heart, Lung and Blood Institute, Bethesda, MD 20892-1762. Phone: 301-496-6887; Fax: 301-402-1542; Email: kovacsm@mail.nih.gov

We have performed a detailed biochemical kinetic and spectroscopic study on a recombinant myosin X head construct to establish a quantitative model of the enzymatic mechanism of this membrane-bound myosin. Our model shows that during steady-state ATP hydrolysis, myosin X exhibits a duty ratio (i.e. the fraction of the cycle time spent strongly bound to actin) of around 16%, but most of the remaining myosin heads are also actin-attached even at moderate actin concentrations in the so-called ‘weak’ actin-binding states. Contrary to the high duty ratio motors myosin V and VI, the ADP release rate constant from actomyosin X is around 5 times greater than the maximal steady-state ATPase activity and the kinetic partitioning between different weak actin-binding states is a major contributor to the rate-limitation of the enzymatic cycle. Two different ADP states of myosin X are populated in the absence of actin, one of which shows very similar kinetic properties to actomyosin•ADP. The nucleotide-free complex of myosin X with actin shows unique spectral and biochemical characteristics, indicating a special mode of actomyosin interaction.

Myosin X is a recently described member of the myosin superfamily that is expressed in vertebrate tissues as a single isoform (1;2). The heavy chain of myosin X consists of an N-terminal motor domain containing the actin and ATP binding sites, a neck region that binds three calmodulin (or possibly other) light chains, a putative coiled-coil region that may bring about heavy chain dimerization and a tail region consisting of several domains of effector function (three pleckstrin homology (PH3) domains, a MyTH4 and a FERM domain) (1). The presence of PH3 domains in the myosin X tail is a unique feature among myosins, and it enables this myosin to directly bind to the plasma membrane via phosphatidyl inositol phospholipids (1;3). Myosin X has been shown to localize to regions of dynamic actin and to exhibit remarkable patterns of intrafilopodial motility (1;4). Interestingly, myosin X localizes to the tips of filopodia, which appears to be an active process requiring myosin X motor function (4). Myosin X induces elongation of filopodia by transporting the Mena/VASP complex (an inhibitor of actin filament capping) to filopodial tips (5). Myosin X activity is also necessary for phagocytosis (6) as well as the localization and function of integrins (7).

The above functional studies indicate a cellular role for myosin X as a plasma membrane-associated cargo transporter. This setting is unique within the myosin superfamily, which implies that this class of motors may have adapted to its role by acquiring distinctive molecular properties. All myosins exert their motile activity during a cyclic interaction with actin filaments and ATP. The enzymatic parameters are key determinants of the motile output of motor proteins, and it has been shown in numerous cases that the biochemistry of different myosins reflects precise and profound functional adaptations to their widely differing...
Kinetic mechanism of myosin X

Study on a heavy meromyosin-like recombinant fragment of myosin X have shown that myosin X exhibits actin-activated ATPase activity and in vitro motility directed towards the barbed end of actin filaments (9). Its mechanism of action, however, has not been investigated in detail. To assess the biochemical and enzymatic properties of myosin X, we used the baculovirus-Sf9 expression system to produce a single-headed myosin X construct (named mX-S1) that retains the catalytically active portion of the molecule. We performed steady-state and transient kinetic, fluorescence spectroscopic and other biochemical measurements to show that myosin X spends a relatively small fraction (16 %) of its ATPase cycle time in the so-called strong actin-binding states. This behavior suggests that myosin X does not use a myosin V-like single-molecule processive stepping mechanism. However, the total actin attachment ratio of myosin X during steady-state ATP hydrolysis is notably high even at moderate actin concentrations (> 50 % attachment at 20 µM actin). This feature is due to the kinetic partitioning between different ‘weak’ actin binding states, which may greatly aid in maintaining continuous actin attachment and therefore proper functioning of a small array of membrane-bound motors.

EXPERIMENTAL PROCEDURES

Cloning, expression and purification of mX-S1 – A truncated (subfragment-1-like) fragment of the bovine myosin X heavy chain cDNA (gift of Dr. David Corey, Harvard Medical School) encoding the motor domain and all three light chain-binding motifs (first 810 amino acids of the heavy chain) was cloned into the pVL1392 expression vector. This construct (referred to as mX-S1 throughout this paper) was co-expressed with calmodulin in the baculovirus-Sf9 expression system. A C-terminal FLAG-tag (sequence: DYKDDDDK) was appended to the heavy chain that enabled high-purity (> 99 %) preparation of recombinant mX-S1. Expression and purification procedures were as described earlier for non-muscle myosin IIA heavy meromyosin (10). Typically, 2-5 mg of mX-S1 could be purified from 4x10⁹ Sf9 cells. Purified mX-S1 was stored in a high ionic strength (I = 525 mM) buffer and used within 4 days of preparation or flash-frozen immediately. The construct was not soluble at low ionic strengths in the absence of actin and nucleotide. Therefore, ionic strengths of > 30 mM had to be used in most experiments. A 2-fold molar excess of extra calmodulin was added to mX-S1 after purification in order to fully saturate the binding sites on the mX-S1 heavy chain, thereby preventing protein aggregation. Protein concentrations were determined using the BioRad assay using smooth muscle myosin subfragment-1 as a standard. Stopped-flow based active site titrations with mantATP indicated that the error of protein concentration determinations was below 10 %.

Other materials – Rabbit skeletal muscle myosin and subfragment-1 (S1) were prepared as in (11) and (12), respectively. Recombinant non-muscle myosin IIB S1 was prepared as described earlier for non-muscle myosin IIA heavy meromyosin (10). Actin was prepared as described in (13) and pyrene-labeled as in (14). Actin filaments were stabilized by addition of a 1.5-fold molar excess of phalloidin (Calbiochem) in all experiments. MantATP and pyrene-iodoacetamide were purchased from Molecular Probes. MDCC-PBP (fluorescently labeled bacterial P₃₅-binding protein) (15) was generously provided by Dr. Howard D. White (Eastern Virginia Medical School). Other reagents were from Sigma.

Fluorescence spectroscopy – Pyrene fluorescence excitation and emission spectra were recorded using a SPEX FluoroMax-3 spectrofluorometer at 25°C in a buffer comprising 20 mM MOPS (pH 7.0), 5 mM MgCl₂, 100 mM KCl and 0.1 mM EGTA (I = 125 mM). In acrylamide quenching, steady-state fluorescence anisotropy and temperature dependence measurements, samples containing pyrene-actin were excited at 347 nm (1 nm bandwidth) and emission was monitored at 406 nm (5 nm bandwidth). Background signal measured with assay buffer alone was
subtracted from all fluorescence records before analysis.

**ActoS1 cosedimentation** – Samples were set up at room temperature in the same buffer conditions as in the spectroscopic measurements (or using 20 mM instead of 100 mM KCl to yield a final I = 45 mM where indicated), and then ultracentrifuged at 100,000 rpm in a Beckman TLA-100 rotor for 15 min at 4°C and the supernatants and pellets run on 4-20 % SDS-PAGE gels. In samples involving ATP but not ADP, contaminating amounts of ADP were removed by the addition of 200 units/ml pyruvate kinase and 1 mM phospho-enolpyruvate. Protein amounts in electrophoretic bands were quantified by densitometric analysis using the Kodak ID 3.5 software.

**Steady-state kinetics** – Steady-state MgATPase activities were measured by a NADH-linked assay as described earlier (16;17) in a buffer containing 4 mM MOPS (pH 7.0), 2 mM MgCl₂, 0.1 mM EGTA, 1 mM ATP, 40 units/ml lactate dehydrogenase, 200 units/ml pyruvate kinase, 1 mM phospho-enolpyruvate, 0.2 mM NADH plus various concentrations of KCl (I = 10 mM + [KCl]). Data were corrected for background ATPase activity of actin.

**Transient kinetics** – Stopped-flow experiments were performed in a KinTek SF-2001 apparatus. Tryptophan fluorescence was excited at 295 nm (6 nm bandwidth) and emission was selected using a 347-nm band-pass filter with a 50 nm bandwidth. Pyrene fluorescence was excited at 365 nm (6 nm bandwidth), and emission monitored through a 400 nm long-pass filter. Light scattering was measured at 420 nm in samples containing pyrene-actin. MantATP was excited using energy transfer from nearby tryptophan residues (excitation at 280 nm with 6 nm bandwidth, emission: 400 nm long-pass filter). MDCC-PBP fluorescence was excited at 436 nm (6 nm bandwidth) and emission collected through a 450 nm long-pass filter. Quenched-flow experiments were performed in a KinTek RQF-3 apparatus using γ-32P-ATP as described earlier (17).

Post-mixing concentrations are indicated throughout the text unless stated otherwise. The volume ratio was 1:1 in all single mixing, and 5:2:5 in double-mixing experiments. Nucleotide-free mX-S1 and acto-mX-S1 were prepared by incubation with 0.01 units/ml apyrase for 15 min at room temperature. In phosphate release measurements, all solutions were preincubated with a ‘P mop’ consisting of 0.02 units/ml purine nucleoside phosphorylase and 0.5 mM 7-methylguanosine.

**RESULTS**

**Basal ATPase mechanism of mX-S1** – In all experiments of the present study we used a single-headed myosin X construct (mX-S1) that contains the catalytically active motor domain as well as the entire neck region comprising three light chain-binding IQ motifs and three calmodulin molecules as light chains.

The tryptophan fluorescence emission of mX-S1 showed a 6 % increase and a small (3 nm) blue shift on the addition of ADP (Fig. 1A). The addition of ATP to mX-S1 caused a similar blue shift and a 20 % fluorescence enhancement compared to the nucleotide-free state, indicating that at least one intermediate of higher fluorescence than the mX-S1.ADP complex is significantly populated during steady-state ATP hydrolysis (Fig. 1A). Mixing mX-S1 with ATP under pseudo first order conditions in the stopped-flow apparatus yielded single exponential tryptophan fluorescence transients (traces not shown). The dependence of the fitted observed rate
constants ($k_{obs}$) of these traces on ATP concentration showed signs of saturation above 250 s$^{-1}$ as shown in Fig. 1B. This behavior suggests that ATP binding to mX-S1 is a two-step process ($K_1$ and $k_2$ in Scheme 1) and the maximal $k_{obs}$ value largely reflects a first-order isomerization step during the binding process ($k_3$). The ATP hydrolysis step ($k_1 + k_{-3}$) is associated with a further increase in tryptophan fluorescence (cf. Scheme 1) and it may therefore have contributions to the ATP binding $k_{obs}$ values of Fig. 1B. The quasi-linear part of the plot at low [ATP] indicated an apparent second order ATP binding rate constant ($k_2/K_1$) of 1.1 µM$^{-1}$s$^{-1}$ (Fig. 1B, Table 1). $k_{obs}$ values for ATP binding obtained monitoring the signal of mantATP, a fluorescently labeled substrate showed a very similar profile to the tryptophan results (Fig. 1B, Table 1).

The time course of transient-state ATP hydrolysis by mX-S1 was followed using the quenched-flow technique. In a single-turnover experiment shown in Fig. 1C, cleavage of ATP followed a biphasic time profile with the fast burst phase being rate-limited by ATP binding and the slow phase by product release that is slower than the ATP cleavage step. The equilibrium constant of ATP hydrolysis in the enzyme-bound state ($K_3$) was 0.3 ± 0.1, as calculated from the amplitude data ($K_3 = A_{fast}/A_{slow}$). The results of multiple turnover quenched-flow experiments in which 1 µM mX-S1 was mixed with a large excess of ATP (50 µM) confirmed the above $K_3$ value and gave a $k_{obs}$ of the burst of 67 ± 15 s$^{-1}$, indicating that ATP binding is still rate-limiting at this ATP concentration (i.e. the ATP hydrolysis rate constant ($k_1 + k_{-3}$) is greater than this $k_{obs}$ value, traces not shown, Fig. 1B, Table 1).

Phosphate release from the mX-S1.ADP.P$_i$ complex was monitored using a fluorescently labeled P$_i$ binding protein (MDCC-PBP). The time course of P$_i$ release on mixing 1 µM mX-S1 with 0.6 µM ATP (single turnover conditions) was single exponential with a $k_{obs}$ of 0.03 s$^{-1}$, a value identical to the steady-state ATPase activity of mX-S1 in the absence of actin, as measured by an NADH-linked coupled assay (traces not shown, Table 1). This indicates that P$_i$ release is rate limiting in the basal (i.e. in the absence of actin) ATPase cycle of mX-S1, with its $k_{obs}$ being determined by the kinetic partitioning in the hydrolysis step ($K_3$) and the fundamental P$_i$ release rate constant ($k_4$) as $k_{obs, pi} = k_4K_3/(1+K_3)$ (Scheme 1, Table 1).

While most of the above features of the basal mX-S1 ATPase cycle are similar to those of other myosins, the ADP interaction of mX-S1 showed some remarkably unusual properties. On mixing mX-S1 with ADP in the stopped-flow under pseudo-first order conditions, the single exponential $k_{obs}$ values of the recorded tryptophan fluorescence transients slightly increased with increasing [ADP] and saturated around the low value of 4 s$^{-1}$ (Fig. 2A). At first glance, the data could seem to indicate a low-affinity single-step binding mechanism with a relatively high intercept ($k_{off} \approx 2$ s$^{-1}$) and a small linear slope ($k_{on} < 0.1$ µM$^{-1}$s$^{-1}$). However, the ADP binding affinity should then be low ($K_a = k_{off}/k_{on} > 20$ µM), which is ruled out by the fact that the amplitudes of the transients showed saturation at much lower ADP concentrations ($K_a = 1.0 \pm 0.2$ µM, Fig. 2A inset). Another possible explanation for the obtained $k_{obs}$ values comes from a two-step model (cf. the right part of Scheme 1 comprising $K_5$ and $K_6$, viewed right to left in the direction of ADP binding). In this model the ADP binding process consists of an initial rapid equilibration ($K_a$, no signal change on this step) followed by a slower reversible isomerization accompanied by a fluorescence increase ($K_5$). The intercept of Fig. 2A will thus be mostly determined by $k_5$ ($\approx 1.5$ s$^{-1}$, going left-to-right in Scheme 1), the maximal $k_{obs}$ will indicate $k_5+k_{-5}$ ($\approx 4.5$ s$^{-1}$), and half-saturation will occur at [ADP] = $K_a$ ($\approx 5$ µM). To further test the validity of this model, we performed ADP "chasing" stopped-flow experiments in which equilibrium mixtures of mX-S1 and ADP were rapidly mixed with mantATP in at least 5-fold excess over ADP to ensure that ADP dissociation after the rapid mix is essentially irreversible (Fig. 2B). The observed mantATP fluorescence transients were biphasic throughout the examined [ADP]
Kinetic mechanism of myosin X

range (Fig. 2B inset). The fractional amplitude of the slow phase \(\frac{A_{\text{slow}}}{(A_{\text{fast}} + A_{\text{slow}})}\) saturated at 0.73 ± 0.02, reaching half-maximum at 1.7 ± 0.2 µM ADP. These data are consistent with the above two-step mechanism inasmuch as the fractional amplitude of the fast phase is determined by the combined fractional population of the M and MD species (cf. Scheme 1) that allow fast binding of mantATP, whereas the slow phase comes from M*D first slowly isomerizing to MD, then losing ADP and binding mantATP. At high [ADP], the \(\frac{A_{\text{fast}}}{A_{\text{slow}}}\) ratio will then equal \(\frac{[\text{MD}]}{[\text{M*D}]}\) (since [M] = 0 in the preincubation mixture) and thus \(K_5 = 0.37 \pm 0.03\). Furthermore at high [ADP], \(k_{\text{fast}}\) and \(k_{\text{slow}}\) will equal \(k_6 (= 15 \text{s}^{-1})\), left-to-right in Scheme 1, cf. Fig. 2B inset) and \(k_5 (= 1.3 \text{s}^{-1})\), respectively. From the experimental data shown in Fig. 2A-B, all rate and equilibrium constants of the two-step ADP binding process can be calculated as shown in Table 1.

Fig. 2C shows experiments that provide a further confirmation of the above model. Here, 0.7 µM mX-S1 was mixed in the stopped-flow with a nucleotide mixture consisting of 50 µM ATP and various ADP concentrations. The resulting tryptophan fluorescence transients were fitted to single exponentials (Fig. 2C inset). It is noteworthy that when the two nucleotides were in equimolar amounts, the \(k_{\text{obs}}\) of the trace (12 s\(^{-1}\), trace 2 in Fig. 2C inset) was only 17 % of that in the absence of ADP (70 s\(^{-1}\), trace 1). This behavior rules out a slow, single-step binding of ADP with a \(k_{\text{obs}}\) around 4 s\(^{-1}\) (cf. Fig. 2A). The open symbols in Fig. 2C show the \(k_{\text{obs}}\) values of single exponential fits to simulated fluorescence transients based on a model of competitive binding of ATP (\(K_1k_2 = 1.4 \mu\text{M}^{-1}\text{s}^{-1}\)) and ADP (\(k_5 = 1.1 \text{s}^{-1}, k_5 = 3.1 \text{s}^{-1}, k_6 = 15 \text{s}^{-1}, k_6 = 3 \mu\text{M}^{-1}\text{s}^{-1}\), cf. Scheme 1, rate constants estimated from the above experimental results) to mX-S1 where the tryptophan fluorescence enhancement assigned to ATP binding was twice that of the MD ↔ M*D transition (no fluorescence change occurs on step 6). The simulated transients were clearly double exponential in most cases, but single exponential approximations were applied because the experimental signal-to-noise ratio did not allow the resolution of multiple phases (cf. Fig. 2C inset). This approximation was fully suitable for the discrimination of the two ADP binding models discussed above.

A ‘chasing’ experiment in which the premixture of 0.7 µM mX-S1 and 50 µM ADP was rapidly mixed with 500 µM ATP gave a tryptophan fluorescence increase transient with a fitted single exponential \(k_{\text{obs}}\) of around 16 s\(^{-1}\) (trace not shown). This value is remarkably higher than the intercept of the ADP binding transients in Fig. 2A. This behavior is consistent with the two-step model described in the previous paragraph, which predicts this experiment to yield a transient consisting of a major phase dominated by \(k_6 (= 15 \text{s}^{-1})\) and a slower phase (\(k_5 \approx 1.2 \text{s}^{-1}\)) with a small amplitude (the two phases did not appear separate due to the low experimental signal-to-noise ratio).

Actin-activation of the steady-state ATPase activity – The steady-state ATPase activity of mX-S1 was ~100-fold activated by actin to a \(V_{\text{max}}\) around 4 s\(^{-1}\) as measured by an NADH-linked coupled enzyme assay (Table 2, Fig. 3). While the \(V_{\text{max}}\) value was fairly independent of solution ionic strength, the actin concentration needed for half-maximal activation (\(K_{\text{ATPase}}\)) markedly increased with increasing ionic strength (Table 2). This behavior is characteristic of myosins in which the so-called weak actin-binding (ATP or ADP.Pi-bound) myosin states are the predominant steady-state intermediates in the actomyosin ATPase cycle. The steady-state data are in line with those reported by Homma et al. for a heavy meromyosin-like myosin X construct (\(V_{\text{max}} = 4.7 \text{s}^{-1}, K_{\text{ATPase}} = 28 \mu\text{M} \text{at 25°C, I} = 40 \text{mM in the absence of Ca}^{2+}\) (9).

Strong-binding interaction of mX-S1 with actin – Actin site-specifically labeled with pyrene at residue C374 has been widely used to probe the so-called strong actomyosin interaction (i.e. that in nucleotide-free actomyosin and in the actomyosin•ADP ternary complex) (18;19). We used this system to monitor the actin interaction of mX-S1. Fig. 4A shows pyrene fluorescence excitation and
Kinetic mechanism of myosin X

emission spectra of free pyrene-actin, pyrene-acto-mX-S1 and pyrene-acto-myosin II S1. These spectra indicate that the large quench (> 60 % at 365 nm excitation) occurring on the binding of myosin II (and other myosins including myosins V and VI) to pyrene-actin results largely from the selective quench of the 360 and 365 nm excitation peaks, consistently with the original study of Kouyama and Mihashi (19). In contrast to this, the smaller (< 30 %) quench on mX-S1 binding to pyrene-actin is not accompanied by a significant change in the relative intensities of the excitation peaks (Fig. 4A). This feature suggests that the strong binding interaction of mX-S1 with actin is structurally different from that of the myosins mentioned above. Addition of 300 µM ATP or ATP$_\gamma$S (nucleotides that induce actomyosin dissociation) to pyrene-acto-mX-S1 fully reversed the fluorescence quench, whereas a partial reversal was observed on adding 300 µM ADP, likely due to partial dissociation of mX-S1 from actin (data not shown).

The small quench in pyrene-acto-mX-S1 is not a result of incomplete saturation of pyrene-actin with mX-S1, as evidenced by fluorescence titrations shown in Fig. 4B. Titration of pyrene-actin with mX-S1 in a spectrofluorometer yielded a small maximal quench (16 %; the extent of the measured fluorescence change was smaller than in Fig. 4A because of the different excitation/emission setup). At saturating mX-S1 concentrations, sequential additions of unlabeled acto-mX-S1 did not further lower the fluorescence of pyrene-acto-mX-S1, which rules out the possibility that the observed decrease in pyrene fluorescence is a light scattering artifact (data not shown). Fig. 4B inset shows a stopped-flow-based amplitude titration where pyrene-acto-mX-S1 was rapidly mixed with excess ATP in order for all mX-S1 to depart from the strong-binding acto-mX-S1 complex. The dissociation constant of mX-S1 binding to pyrene-actin calculated from the experiments in Fig. 4B ($K_A = 0.14 \pm 0.05$ µM, cf. Scheme 2, Table 4) was remarkably higher than that of other myosins studied ($K_A$ usually falls between 10 pM and 10 nM) (17;20-26).

Further fluorescence characterization also indicated a unique mode of interaction of mX-S1 with pyrene-actin in the absence of nucleotide. Acrylamide quenching measurements showed that the Stern-Volmer quenching constant of pyrene-actin reduced 5-10-fold on binding to different myosin II isoforms (Table 3), reflecting a marked reduction in the solvent exposure of the pyrene fluorophore attached to C374 of actin. The reduction was much smaller (2.5-fold) in the case of mX-S1 (Table 3). Also, the steady-state fluorescence anisotropy of the pyrene-acto-mX-S1 complex showed an intermediate value between those of free pyrene-actin and pyrene-actomyosin II S1, although the differences were small (Table 3). The temperature dependence of pyrene-acto-mX-S1 fluorescence intensity (both in the absence of nucleotide and in the presence of 300 µM ADP) closely paralleled that of free pyrene-actin: it decreased by ~1 % per 1 °C temperature increase between 5°C and 25°C, which is likely due solely to a physical effect and not to protein conformational changes (data not shown) (27). This result rules out the possibility that the limited effect of mX-S1 binding on pyrene-actin fluorescence (intensity, solvent exposure, anisotropy) would come from temperature-sensitive conformational heterogeneity.

We investigated the kinetics of pyrene-actin binding to mX-S1 by mixing the two proteins under pseudo first order conditions in the stopped-flow (Fig. 4C). The dependence of $k_{obs}$ values of single exponential fits to the pyrene fluorescence transients delineated an ~8-fold slower second order binding rate constant in the presence of ADP ($k_{DA} = 0.26 \pm 0.02$ µM$^{-1}$s$^{-1}$) than in the absence of nucleotide ($k_A = 2.1 \pm 0.2$ µM$^{-1}$s$^{-1}$) (Table 4, Scheme 2). The off-rate constants ($k_A, k_{DA}$) determined by the intercepts of the plots were in the range of 0.4–1 s$^{-1}$, which is a surprisingly high value in the absence of nucleotide (Table 4). We directly measured the off-rate constants by ‘chasing’ stopped-flow experiments in which pyrene-acto-mX-S1 was mixed with excess unlabeled actin (Fig. 4D). The fitted $k_{obs}$ values of the recorded single exponential transients showed that mX-S1 indeed dissociates.
Kinetic mechanism of myosin X

unusually rapidly from pyrene-actin in the absence of nucleotide ($k_a = 0.41 \pm 0.10 \text{ s}^{-1}$), and the off-rate constant is not significantly influenced by the presence of ADP ($k_{DA} = 0.34 \pm 0.03 \text{ s}^{-1}$, Table 4). The equilibrium constant of nucleotide-free mX-S1 binding to pyrene-actin calculated from the off- and on-rate constants ($K_A = 0.20 \text{ µM}$) was in good agreement with the results of the equilibrium titration experiments of Fig. 4B (Table 4).

Stopped-flow equilibrium titrations of the type shown in Fig. 4B inset in the presence of 100 µM ADP yielded a $K_{DA}$ of $1.0 \pm 0.2 \text{ µM}$ (data not shown), also in reasonable agreement with the ratio of the off- and on-rate constants (Table 4).

ATP-induced acto-mX-S1 dissociation, ATP hydrolysis and the weak actin-binding interaction – The ATP-induced dissociation of mX-S1 from pyrene-actin was followed by monitoring both pyrene fluorescence and light scattering. The changes in the two signals had opposite signs (pyrene fluorescence increased, light scattering decreased upon pyrene-acto-mX-S1 dissociation) and showed nearly identical dependence of the single exponential $k_{obs}$ values on ATP concentration (Fig. 5A). This behavior shows that the dissociation of mX-S1 from pyrene-actin immediately follows the transition from a strongly to a weakly actin-bound state ($k_T + k_{-T} > k_2'$ in Scheme 3).

Similarly to other myosins, $k_{obs}$ showed saturation at a high value ($k_2' > 600 \text{ s}^{-1}$), indicating that ATP binding to acto-mX-S1 is a two-step process ($K_{1'}$ and $k_2'$, Scheme 3, Table 4). The apparent second order ATP binding rate constant ($k_2'/K_{1'}$) was markedly reduced with increasing ionic strength ($0.55 \pm 0.04 \text{ µM}^{-1}\text{s}^{-1}$ at $I = 125 \text{ mM}$ as opposed to $1.8 \pm 0.2 \text{ µM}^{-1}\text{s}^{-1}$ at $I = 35 \text{ mM}$, Fig. 5A, Table 4).

We performed multiple turnover quenched-flow experiments to assess the transient kinetics of the hydrolysis of ATP after it binds to acto-mX-S1. The observed time courses of $P_i$ production on mixing acto-mX-S1 with excess ATP comprised a single exponential burst with a linear steady-state phase (Fig. 5B). The $k_{obs}$ of the burst phase was similar to that of the corresponding pyrene fluorescence and light scattering records both at 10 µM and 50 µM ATP (Fig. 5B). This shows that the ATP binding process is rate-limiting at these concentrations, consistently with the fast actin-detached ATP hydrolysis rate constant ($k_3 + k_{-3} > 80 \text{ s}^{-1}$, cf. Fig. 1B, Table 4). The amplitude of the burst (0.25 mol $P_i / \text{mol mX-S1}$) was similar to that in the quenched-flow experiments performed in the absence of actin (Figs. 1C and 5B).

We assessed the fractional binding of mX-S1 to actin during steady-state ATP hydrolysis by SDS-PAGE analysis following sedimentation of actin-bound mX-S1 by ultracentrifugation (Fig. 5C). mX-S1 showed notably high steady-state actin attachment even at moderate actin concentrations and in the absence of any ADP ‘background’ (50 % attachment was attained at around 8 µM and 13 µM actin at ionic strengths of 45 mM and 125 mM, respectively, Fig. 5C). Inclusion of ADP in the steady-state mixture (at an ATP:ADP ratio of 10:1) caused a further increase in actin attachment (Fig. 5C). As expected from the transient kinetics of mX-S1,ADP binding to actin ($K_{DA} = 1-2 \text{ µM}$, Fig. 4C, Table 4), practically all mX-S1 was bound to actin even at low actin concentrations in the presence of 200 µM ADP when ATP was not present (Fig. 5C).

Actin-activation of phosphate release – We investigated the kinetics of $P_i$ release from acto-mX-S1 by double-mixing single turnover stopped-flow experiments in which mX-S1 was first mixed with substoichiometric amounts of ATP (typically, 2 µM mX-S1 and 1 µM ATP was present after the first mix), incubated for 1–3 s for ATP binding and hydrolysis to occur, and then mixed with a range of actin concentrations. $P_i$ release was monitored using a fluorescently-labeled phosphate binding protein (MDCC-PBP) (15) present at a concentration of 4 µM in all syringes in all experiments. The ionic strength was reduced to 45 mM in these experiments to obtain measurable (i.e. relatively higher) affinities of the weak-binding mX-S1 states to actin ($K_T$ and $K_{DP}$ in Scheme 3). The transients recorded after the second rapid mix were single exponential at low actin concentrations,
but at higher [actin] two separate phases were observed (Fig. 6A). The \( k_{\text{obs}} \) of the slow phase saturated around 1 s\(^{-1}\), whereas the fast phase \( k_{\text{obs}} \) increased with increasing actin concentration to \( > 20 \text{ s}^{-1} \) at 50 \( \mu \text{M} \) actin, showing signs of saturation (Fig. 6A).

Similarly to the work of White et al. on skeletal muscle myosin II S1 (28), we interpret this biphasic behavior as a result of the following processes. After the first mix, an equilibrium mixture of the pre- and post-hydrolysis MT and MDP states forms (Scheme 1). Upon mixing with actin, the fast phase of the MDCC-PBP fluorescence transients arises from actin binding of MDP (\( K_{\text{DP}} \), Scheme 3) followed by the release of P\(_i\) from the AMDP quaternary complex (\( k_{4'} \)). The \( k_{\text{obs}} \) of this phase will be defined as \( k_{4'} \) [actin]/(\( K_{\text{DP}} \) + [actin]). The slow phase splits off at higher actin concentrations as a result of the presence of an alternative pathway in which actin-attached ATP hydrolysis (\( k_{3'} + k_{-3'} \approx 1 \text{ s}^{-1} \), Scheme 3) limits the rate of the oncoming phosphate release and thus determines the \( k_{\text{obs}} \) of the slow phase of the transients. The fractional amplitudes of the fast and slow phases (~30 % fast phase, Fig. 6B inset) remained more or less constant throughout the examined actin concentration range and are in line with the actin-detached ATP hydrolysis equilibrium constant (\( K_{3} = 0.3 \pm 0.1 \), Table 1). Lowering the ATP concentration to 0.5 \( \mu \text{M} \) after the first mix did not affect the \( k_{\text{obs}} \) values and fractional amplitudes (data not shown), demonstrating that the slow phase is not a result of binding of a second ATP molecule to mX-S1 because of an accidental molar excess of ATP over mX-S1 (e. g. because of a possible error in protein concentration).

Phosphate release experiments at 125 mM ionic strength similar to the ones described above yielded single exponential MDCC-PBP fluorescence transients whose \( k_{\text{obs}} \) increased slowly with increasing actin concentration to a small value of 1.3 s\(^{-1}\) at 33 \( \mu \text{M} \) actin (Fig. 6C). We surmise that at this higher ionic strength both MT and MDP (Scheme 3) have very low actin affinities and thus the two phases of P\(_i\) release do not separate.

In a multiple turnover single mixing stopped-flow experiment in which 20 \( \mu \text{M} \) actin and 1 \( \mu \text{M} \) mX-S1 was mixed with 50 \( \mu \text{M} \) ATP at \( I = 125 \text{ mM} \), a linear P\(_i\) release time profile was observed with no exponential burst phase (data not shown). This behavior indicates that the net rate of P\(_i\) release (influenced by all of the parameters \( k_{3'} + k_{-3'}, K_{3}, K_{P}, K_{DP} \) and \( k_{4'} \), Scheme 3) is rate-limiting in the steady-state ATPase cycle in these conditions, in line with the results of the double-mixing experiments discussed above.

**ADP interaction of acto-mX-S1** — ADP binding to and release from pyrene-acto-mX-S1 did not result in a change in pyrene fluorescence, similarly to other myosins (data not shown). Therefore, we monitored the ADP interaction kinetics of acto-mX-S1 by utilizing the inhibitory effect of ADP on the ATP-induced dissociation of the pyrene-acto-mX-S1 complex. In a set of experiments shown in the main panel of Fig. 7A, premixtures of 0.2 \( \mu \text{M} \) pyrene-actin, 0.25 \( \mu \text{M} \) mX-S1 and various ADP concentrations were rapidly mixed with 300 \( \mu \text{M} \) ATP in the stopped-flow (pre-mixing concentrations stated), and the resulting dissociation of mX-S1 from pyrene-actin was monitored by recording pyrene fluorescence increase transients. As a function of [ADP] in the premixure, the fitted single exponential \( k_{\text{obs}} \) values of the transients rapidly decreased from 96 s\(^{-1}\) in the absence of ADP to about 20 s\(^{-1}\) at 1 \( \mu \text{M} \) ADP, and \( k_{\text{obs}} \) further converged to zero with increasing ADP concentration (Fig. 7A). The reduction of \( k_{\text{obs}} \) with increasing [ADP] can be deduced from two main causes. First, the rate constant of ADP dissociation from acto-mX-S1. ADP may be lower than that of the ATP-induced dissociation of pyrene-acto-mX-S1 at the ATP concentration used (\( k_{\text{AD}} < 96 \text{ s}^{-1} \)), and thus limit the rate of the reaction as the acto-mX-S1. ADP ternary complex becomes predominant at high [ADP] in the premixture (Scheme 4 depicts the kinetic steps involved in this process). Secondly, with increasing [ADP], the transient rebinding of ADP instead of ATP to pyrene-acto-mX-S1 may inhibit the ATP-induced acto-S1 dissociation reaction (even if \( k_{\text{AD}} > 96 \text{ s}^{-1} \)). Theoretically, if ADP release from acto-S1
is slower than ATP binding, then double exponential transients are to be expected with the fast phase arising from acto-S1 dissociation caused by ATP binding to ADP-free acto-S1 ([ATP]k_2/K_1' = 96 s^{-1}), and the slow phase representing acto-S1 dissociation through the AMD \rightarrow AM \rightarrow AMT pathway where the first ADP dissociation step (k_{AD}) is rate-limiting (Scheme 4). The two phases, however, may not be resolvable because of the relatively low experimental signal-to-noise ratio due to the small pyrene fluorescence change (see Fig. 4 and the trace shown in Fig. 7B inset). Therefore, further experiments were necessary to obtain the ADP dissociation and association rate constants (k_{AD}, k_{-AD}). The inset of Fig. 7A shows the k_{obs} values of single exponential fits to the pyrene fluorescence transients recorded on rapidly mixing 0.15 µM pyrene-actin plus 0.2 µM mX-S1 with a nucleotide mixture consisting of 200 µM ATP plus the indicated ADP concentrations (pre-mixing concentrations indicated). As discussed in a recent detailed investigation of the ADP interaction of pyrene-actomyosin VI (29), double exponential transients would be expected in this reaction, but the two phases were not resolved in our experiments. Nevertheless, the initial (zero [ADP]) k_{obs} decreased to half at 30 µM ADP (Fig. 7A inset).

The k_{obs} of pyrene-acto-mX-S1 dissociation will equal the ADP release rate constant (k_{AD}) if an ADP-saturated pre-mixture ([AMD] \gg [AM], Scheme 4) is rapidly mixed with such a large excess of ATP that ADP rebounding after the mix will not contribute to the transient (i.e., [ATP]k_2/K_1' \gg [ADP]k_{-AD}). To achieve such conditions we rapidly mixed a premixture of 0.15 µM pyrene-actin, 0.2 µM mX-S1 and a relatively high concentration of ADP (50 µM, pre-mixing concentrations stated) with increasing concentrations of mantATP in the stopped-flow, and the binding of mantATP to acto-mX-S1 was monitored by the increase in mantATP fluorescence (Fig. 7C). Similarly to the experiments of Fig. 7B, the ADP dissociation rate constant from acto-mX-S1 (k_{AD}) will limit the k_{obs} of the process at high mantATP concentrations (cf. Scheme 4). The fitted maximal k_{obs} in these experiments was 18.8 s^{-1} (Fig. 7C), in agreement with the results of Fig. 7B.

**DISCUSSION**

**Steady-state distribution of acto-mX-S1 ATPase intermediates** – We used the determined biochemical parameters to establish a kinetic model of the entire acto-mX-S1 ATPase cycle that can serve as a basis for calculations of functionally important steady-state parameters and predictions of the motile behavior of this myosin. A chief component of the actin-activation of the mX-S1 ATPase is a robust (~700-fold) acceleration of phosphate release from the mX-S1.ADP.P_i products complex by actin (k_4 = 0.13 s^{-1}, k_4' \approx 90 s^{-1}, Schemes 1 and 3, Tables 1 and 4). However, both the rate constant of P_i release
from acto-mX-S1 \( (k'_4) \) and the ADP release rate constant \( (k_{AD} = 18 \pm 1 \text{ s}^{-1}) \) are markedly greater than the maximal steady-state ATPase activity of acto-mX-S1 \( (4–5 \text{ s}^{-1}, \text{Table 2}) \). Other steps such as ATP binding to acto-mX-S1, dissociation of acto-mX-S1 or actin-detached ATP hydrolysis are also too fast to act as a single rate-limiting step of the enzymatic cycle. The contributions of multiple processes to steady-state rate-limitation can therefore be determined only by global numerical analysis of the enzymatic cycle.

A large majority of the elementary rate constants used in the numerical analysis could be directly extracted from the experimental data. Large uncertainties remain in only two parameters: the equilibrium constant of the actin-attached ATP hydrolysis step \( (K_3' \text{ in Scheme 3}) \) and the actin affinity of the mX-S1.ATP complex \( (K_T) \). We could determine both \( K_3 \) and \( K_{DP} \) with reasonable accuracy and therefore the values for \( K_3' \) and \( K_T \) must be interdependent to maintain thermodynamic consistency \( (K_3'/K_T = K_3/K_{DP}) \). The actin concentration dependences of the steady-state acto-mX-S1 ATPase activity (Fig. 3) and actin attachment ratio (Fig. 5C) were used as experimental steady-state data for parameter optimization of \( K_3' \) and \( K_T \). (Note that the total actin attachment ratio is the sum of the fractional abundances of all actin-attached steady-state intermediates (AM, AMT, AMDP and AMD in Scheme 3) and thus it is different from the duty ratio, which is the sum of the fractional abundances of only the strongly actin-bound states (AM and AMD).) Data related to an ionic strength of 45 mM were considered for the analysis because \( K_{DP} \) was determined at this ionic strength and the actin affinity of the weak actin binding myosin states \( (K_T, K_{DP}) \) are generally the parameters having a marked dependence on solution ionic strength. Simulations in which \( K_T \) was set to the same value as \( K_{DP} \) \((= 160 \mu \text{M}) \) and \( K_3' \) was thus defined \( 0.3 \) \((= K_3/K_{DP}) \) yielded a steady-state ATPase activity having a plateau \( (V_{\text{max}}) \) around 4.5 s\(^{-1}\) with half-saturation at 30 μM actin \( (K_{\text{ATPase}}) \). These values correspond reasonably well with the experimental data (a \( V_{\text{max}} \) of 3–5 s\(^{-1}\) and a \( K_{\text{ATPase}} \) of 15–30 μM is expected (Table 2)). However, the simulated steady-state actin attachment ratio was much lower than the experimental one \((50 \% \text{ attachment was reached at } 65 \mu \text{M actin in the simulation as opposed to the experimental } 10–15 \mu \text{M (Fig. 5C)}) \). Therefore we next lowered \( K_T \) 10-fold \((to 13 \mu \text{M}) \), accompanied by a 10-fold reduction in \( K_3' \) \((to 0.03) \). These parameters resulted in a steady-state ATPase that rapidly saturated with increasing actin concentration \( (K_{\text{ATPase}} = 7 \mu \text{M}) \), but its maximal value \( (V_{\text{max}} = 1.3 \text{ s}^{-1}) \) was well below the experimental one. A model with intermediate values in which \( K_T \) was set to 43 μM and \( K_3' \) to 0.1, showed reasonably good agreement with the experimental data with regard to all three parameters \( (the \text{model yielded a } V_{\text{max}} \text{ of } 3.5 \text{ s}^{-1} \text{ and a } K_{\text{ATPase}} \text{ of } 15 \mu \text{M}, \text{with half-saturation of actin attachment occurring at } 25 \mu \text{M actin, Fig. 8}). \)

It is remarkable that the actin attachment ratio during steady-state ATP hydrolysis shows half-saturation at an actin concentration \((25 \mu \text{M}) \) that is well below the dissociation constants of both weak actin binding mX-S1 states \( (K_T = 43 \mu \text{M, } K_{DP} = 130 \mu \text{M}) \), and the presence of the strongly actin-bound AMD species \( (\text{with a fractional occupancy of } 10 \% \text{ at } 25 \mu \text{M actin}) \) has only a limited contribution to this phenomenon. At low actin concentrations, the detached MT and MDP states are the predominant steady-state intermediates. With increasing actin concentration, the AMT and, to a more limited extent, the AMD species become the most abundant ones.

The predominance of the AMT complex in the steady-state mixture has two important and somewhat unusual consequences. First, the classically defined duty ratio, which in this case practically equals the fractional occupancy of AMD, will have a maximal value of 16 % at around 100 μM actin, but with a further increase in actin concentration it then declines to a value around 6 % (Fig. 8). Secondly, the steady-state ATPase activity will also decline at very high actin concentrations and reach a final value rate-limited by actin-attached ATP hydrolysis \( (k_4' + k_3' \approx 1 \text{ s}^{-1}, \text{Fig. 8}) \). Unfortunately, the experimental demonstration of these phenomena is strongly hindered by major technical difficulties.
because the pyrene-actin signal change on mX-S1 binding (that could be used for duty ratio measurement) is small and the reduction in the steady-state ATPase activity becomes significant only at actin concentrations well above 200 µM.

Another important feature predicted by the model is that the presence of even high concentrations of ADP will have only a limited effect on the steady-state properties of acto-mX-S1. At 100 µM actin and an ATP concentration of 1 mM, the introduction of an 1 mM ADP ‘background’ into the steady-state simulation only decreased the acto-mX-S1 ATPase activity by 20 % and caused a small increase in the total actin attachment ratio (from 73 % to 76 %), but the duty ratio was notably elevated (from 16 % to 28 %).

As an alternative to the above model, it is conceivable that a slow isomerization between two different ADP-bound acto-mX-S1 states (which would occur between steps k4' and kAD in Scheme 3) could limit the steady-state flux through the ATPase cycle. Such a step would remain undetected in the experiments of Fig. 7 if it was highly favorable in the left-to-right direction in Scheme 3. (In this case, only the ‘post-step’ species would be represented in the acto-mX-S1.ADP premixtures.) However, the strong dependence of the steady-state K_{ATPase} on ionic strength (Table 2) and the absence of a rapid burst phase of P_i release in single-mixing stopped-flow experiments indicate that the kinetic partitioning between the weak actin-binding intermediates is a major determinant of the steady-state rate even in this case. Thus, in order to maintain a steady-state V_{max} around 4 s^{-1}, the rate constant of this hypothetical acto-mX-S1.ADP isomerization must be in the same range (or faster) than the k_{AD} value determined in this study (18 s^{-1}).

Taken together, the data show that the main kinetic pattern of myosin X is different from that of the high duty ratio motors myosin V and VI (25;26): its duty ratio is lower and the entry into the strong-binding AMD state contributes more to steady-state rate-limitation than the exit from this state (i. e. ADP release). These findings are consistent with the results of Homma et al. showing that, unlike myosin V, a double-headed myosin X construct showed in vitro motile activity only at fairly high surface densities and the presence of ADP had little effect on its ATPase activity (9). On the other hand, the predicted maximal duty ratio of myosin X (16 %) is notably higher than that of skeletal and smooth muscle myosins (4 %) (30), in line with the fact that the surface density required for smooth muscle myosin II in vitro motility was even higher than in the case of myosin X (9).

Two ADP-bound states of mX-S1 – We present kinetic evidence showing that mX-S1 adopts at least two different ADP-bound structural states in the absence of actin (see Scheme 1). Analysis of our transient kinetic data indicates that one of the ADP states (MD) has a tryptophan fluorescence intensity similar to that of nucleotide-free mX-S1, whereas the other state (M*D) exhibits a slightly elevated fluorescence intensity (by about 10 %). The two states are in reversible equilibrium (K_5 = 0.37 ± 0.03 at 25°C and I = 125 mM, Table 1). The existence of multiple ADP-bound states has been demonstrated in the case of several myosin II isoforms (31;32). However, their rate constant of interconversion in mX-S1 (k_5 + k_5 ≈ 4 s^{-1}) is about 50-fold smaller than those reported for myosin II. Based on the fact that ATP causes a ~3-fold larger increase in tryptophan fluorescence than ADP, we propose that the MD ↔ M*D step (K_5) is different from the transition between the crystallographically identified switch II open-to-closed transition that is coupled to ATP hydrolysis and is accompanied by a large rotation of the neck (lever arm) region (this transition is likely to occur on the M*T ↔ M**DP step (K_3 in Scheme 1) (33)). Myosin X possesses the so-called relay loop tryptophan (W481 in mX-S1) that has been shown to be sensitive to both nucleotide binding and the open-closed transition in various myosin II isoforms (34-38), whereas it lacks tryptophans at the nucleotide binding pocket that also showed fluorescence changes on nucleotide binding to skeletal muscle myosin II (W113 and W131 in skeletal myosin) (37). Thus, it is likely that the tryptophan fluorescence changes during the mX-S1 ATPase cycle are largely due to W481.
It is noteworthy that, uniquely among myosins, myosin X has another tryptophan residue in the relay loop (W486) that is conserved within this class (the homologous position is occupied by other aromatic residues in myosin II and most other myosins (39)). Another potentially sensitive tryptophan residue in mX-S1 that is missing from myosin II is located at the basis of the lever arm (W717; this tryptophan is present in some myosin I, III, VII, XIII and XIV isoforms (39)).

The first step of ADP binding to mX-S1 (M $\leftrightarrow$ MD transition, $K_a$ in Scheme 1) exhibits strikingly similar kinetic parameters to the acto-mX-S1 ADP binding step ($K_{AD}$ in Scheme 3) (on-rates: $2.1\text{--}4.3 \mu M^{-1}s^{-1} (k_\phi)$ versus $2.1 \mu M^{-1}s^{-1} (k_{AD})$, off-rates: $13\text{--}16 s^{-1} (k_\phi)$ versus $18 s^{-1} (k_{AD})$, equilibrium constants: $3.7\text{--}6.3 \mu M (K_\phi)$ versus $8.4 \mu M (K_{AD})$). It can thus be inferred that the strong-binding interaction of mX-S1 with actin causes little or no change in the structural dynamics of ADP binding into the nucleotide pocket of mX-S1 and the MD state (which is significantly populated in the absence of actin) may be structurally very similar to the acto-mX-S1.ADP ternary complex (AMD state). Actin thus does not accelerate ADP release step per se, but it rather changes the conformational distribution of mX-S1.ADP and favors a lower ADP affinity state (MD) that is present even in the absence of actin. (One may even surmise that the M*D state is off the main pathway of the basal mX-S1 ATPase cycle and represents only a side-branch. Such an alteration in the mechanism would not change the ATP-related kinetic behavior of the enzyme.) The absence of a marked acceleration of the ADP release step by actin is not without precedent in the myosin superfamily: non-muscle myosin IIA (21), IIB (17) as well as myosins I (23;24), V (25), and VI (26) show rigor dissociation constants in the nanomolar range and the dissociation rate constants fall usually below $0.01 s^{-1}$ under similar temperature and ionic strength conditions to those in the current study. An intriguing exception is skeletal muscle myosin, which showed a very similar profile to mX-S1 ($K_a = 0.11 \mu M$, $k_A = 0.22 s^{-1}$ at $20^\circ C$, $I = 125 mM$) in the pyrene fluorescence study of Criddle et al (18). Despite a number of recently published studies (41-44), views about the atomic structure of the rigor actomyosin complex are still controversial even in the case of the best-studied myosin II class. To assess the structural basis of the unusual fluorescent and kinetic properties of pyrene-acto-mX-S1, we made amino acid sequence comparisons of the major structural elements of the actin-binding interface of myosins II and X (Fig. 9).

The helix-turn-helix motif of the strong actin-binding interface is the myosin structural element that directly interacts with the actin segment that contains the C374 residue carrying the pyrene fluorophore. Interestingly, this region of myosin is fairly conserved between classes II and X (Fig. 9). The major differences between the primary structure of the actin interface of myosins II and X locate to regions more distant from the pyrene fluorophore attachment site, primarily to the so-called cardiomyopathy loop and, to a lesser extent, to loop 3. It is thus not possible to simply relate the spectral differences of pyrene-acto-S1 complexes to differences in the sequence of a limited set of amino acid position(s) that directly interact with the fluorophore. The spectral and kinetic differences possibly result from differences in the large-scale structural dynamics of the actomyosin interface. We could not identify acto-mX-S1 conformational substrates in our interaction with different myosin II isoforms (Fig. 4A, Table 3), the acto-mX-S1 affinity is remarkably low ($K_a = 0.14 \pm 0.05 \mu M$, Fig. 4B, Table 4) and the off-rate constant of mX-S1 from pyrene-actin is fast ($k_A = 0.41 \pm 0.10 s^{-1}$, Fig. 4D). Most myosin isoforms investigated to date including smooth muscle myosin II (20), vetebrate non-muscle myosin II (17;21), Dictyostelium myosin II (22) as well as myosins I (23;24), V (25), and VI (26) show rigor dissociation constants in the nanomolar range and the dissociation rate constants fall usually below $0.01 s^{-1}$ under similar temperature and ionic strength conditions to those in the current study. An intriguing exception is skeletal muscle myosin, which showed a very similar profile to mX-S1 ($K_a = 0.11 \mu M$, $k_A = 0.22 s^{-1}$ at $20^\circ C$, $I = 125 mM$) in the pyrene fluorescence study of Criddle et al (18). Despite a number of recently published studies (41-44), views about the atomic structure of the rigor actomyosin complex are still controversial even in the case of the best-studied myosin II class. To assess the structural basis of the unusual fluorescent and kinetic properties of pyrene-acto-mX-S1, we made amino acid sequence comparisons of the major structural elements of the actin-binding interface of myosins II and X (Fig. 9). The helix-turn-helix motif of the strong actin-binding interface is the myosin structural element that directly interacts with the actin segment that contains the C374 residue carrying the pyrene fluorophore. Interestingly, this region of myosin is fairly conserved between classes II and X (Fig. 9). The major differences between the primary structure of the actin interface of myosins II and X locate to regions more distant from the pyrene fluorophore attachment site, primarily to the so-called cardiomyopathy loop and, to a lesser extent, to loop 3. It is thus not possible to simply relate the spectral differences of pyrene-acto-S1 complexes to differences in the sequence of a limited set of amino acid position(s) that directly interact with the fluorophore. The spectral and kinetic differences possibly result from differences in the large-scale structural dynamics of the actomyosin interface. We could not identify acto-mX-S1 conformational substrates in our interaction.

Spectral and kinetic properties of the pyrene-acto-mX-S1 complex – Our pyrene-actin fluorescence studies indicate that the rigor (nucleotide-free) complex of mX-S1 with actin shows several distinctive features. The spectral changes of pyrene-actin on binding to mX-S1 are markedly different than those on
steady-state fluorescence measurements. Future time-resolved fluorescence studies will likely yield insights into these properties, and the distinctive features of myosin X may also contribute to our general view of the actomyosin interaction.

Role of the biochemical properties of mX-S1 in cellular functions – Myosins exert their motile activity during cyclic interaction with actin. As emphasized in a recent review on the biochemical adaptations of myosins to different cellular environments, a supramolecular ensemble of any myosin must be able to maintain continuous attachment to actin during a contractile event that may span a large number of enzymatic cycles and corresponding mechanical steps (8). That is, each myosin isoform must be processive as a functional unit to be capable of motile activity.

A unique feature of myosin X within the myosin superfamily is that among its various effector domains in the tail region, it has three pleckstrin-homology (PH3) domains that bind to membrane phospholipids. Therefore, this myosin probably exerts its cellular functions in a markedly different supramolecular organization from that of many other actin-based motors, e.g. the thick filaments of myosin II or the single-molecule motility of myosin V. The predicted maximal duty ratio of myosin X is 16 % (in the absence of ‘background’ ADP), which implies that myosin X would not be able to perform myosin V-like double-headed single molecule stepping, for which a strong (stereospecific) attachment of at least one of the heads to actin at any time and therefore a single-headed duty ratio of at least 50 % is a prerequisite. Regardless of this, the full-length myosin X molecule is predicted to be double-headed based on the presence of a putative coiled-coil region in the tail domain. However, based on recent doubts about the dimeric nature of myosin VI, one must use caution regarding such predictions based on amino acid sequence (45). Whereas the dimerization of heavy chains is probably of functional significance, the membrane-attached nature of myosin X is likely to be the main determinant of the functional constraints imposed on this motor.

A small array of membrane-bound myosin X molecules (consisting of at least 8-10 heads) with a duty ratio of 0.16 may already be capable of processive movement. Furthermore, it is reasonable that there would be no strong demand for a high duty ratio in a tight spatial arrangement of the actin cytoskeleton and the plasma membrane (especially in filopodia), since such an arrangement can effectively prevent the diffusion of myosin X away from the actin filament. Correspondingly, an elegant recent study has demonstrated the importance of PH domain-mediated membrane attachment in motor function and processivity of the KIF1A kinesin isoform (46).

It is an intriguing possibility that myosin X may be capable of diffusive sliding along actin in the weakly actin-attached states that are the most abundant steady-state intermediates; whereas cyclic powerstrokes carried out in a strongly (stereospecifically) actin-bound state could ensure a net directionality of the movement towards the barbed end of the actin filament. Such a behavior may be related to the interesting ‘back-and-forth’ patterns of intrafilopodial motility of myosin X-containing puncta in vivo (4). It may also be of interest to determine whether the weak actin-binding states of myosin X are in rapid equilibrium with actin as they are in the case of myosin II, or the rate of actin detachment of these states is also a significant determinant of the motile properties. It should also be noted that the biochemical properties and low calculated duty ratio of the single-headed mX-S1 construct presented in the current work do not provide a simple explanation to the fact that a heavy meromyosin-like (double-headed) myosin X construct appears to be able to actively move out to filopodial tips, presumably as a single molecule in the absence of a tail that could provide membrane attachment (4). It is possible that in double-headed myosin X, a strain-sensitive head-head coordination mechanism influences the rate constants of nucleotide binding and/or dissociation, thereby increasing processivity. Such effects have been demonstrated in the case of myosins V and VI (29;47;48).

While myosin X actively moves out to the tips of filopodia (and so does myosin XVa to
stereocilial tips), other motors such as myosin V do not show this behavior (4;49). A biochemical explanation for this difference could be that the actin interaction of myosin X (and possibly XVα) is regulated by a specific set of actin-associated proteins (e.g., various isoforms of tropomyosin) that do not have a similar effect on the motility of other motors such as myosin V. A series of important questions regarding the function and mechanism of myosin X remain to be addressed in future cell biological and biochemical/biophysical studies.

ACKNOWLEDGMENTS

We thank Dr. David Corey (Harvard Medical School) for the bovine myosin X cDNA clone, Lingfong Chen for engineering the DNA construct for mX-S1, Dr. Howard White (Eastern Virginia Medical School) for the gift of MDCC-PBP, Estelle V. Harvey, Yue Zhang and Antoine F. Smith for expert technical assistance and Judit Tóth for discussions.

ABBREVIATIONS

I, ionic strength; k_{obs}, observed rate constant; mant, methylanthraniloyl-; MDCC-PBP, fluorescently labeled bacterial phosphate binding protein; MOPS, N-morpholino-propanesulfonic acid; mX-S1, recombinant subfragment-1 like bovine myosin X construct; P_i, inorganic phosphate; S1, subfragment-1.

REFERENCES

1. Berg, J. S., Derfler, B. H., Pennisi, C. M., Corey, D. P., and Cheney, R. E. (2000) J. Cell Sci. 113 Pt 19, 3439-3451
2. Berg, J. S., Powell, B. C., and Cheney, R. E. (2001) Mol. Biol. Cell 12, 780-794
3. Mashanov, G. I., Tacon, D., Peckham, M., and Molloy, J. E. (2004) J. Biol. Chem. 279, 15274-15280
4. Berg, J. S. and Cheney, R. E. (2002) Nat. Cell Biol. 4, 1103-1107
5. Tokuo, H. and Ikebe, M. (2004) Biochem. Biophys. Res. Commun. 319, 214-220
6. Cox, D., Berg, J. S., Cammer, M., Chinegwundoh, J. O., Dale, B. M., Cheney, R. E., and Greenberg, S. (2002) Nat. Cell Biol. 4, 469-477
7. Zhang, H., Berg, J. S., Li, Z., Wang, Y., Lang, P., Sousa, A. D., Bhaskar, A., Cheney, R. E., and Stromblad, S. (2004) Nat. Cell Biol. 6, 523-531
8. De La Cruz, E. M. and Ostap, E. M. (2004) Curr. Opin. Cell Biol. 16, 61-67
9. Homma, K., Saito, J., Ikebe, R., and Ikebe, M. (2001) J. Biol. Chem. 276, 34348-34354
10. Wang, F., Harvey, E. V., Conti, M. A., Wei, D., and Sellers, J. R. (2000) Biochemistry 39, 5555-5560
11. Margossian, S. S. and Lowey, S. (1982) Methods Enzymol. 85 Pt B, 55-71
12. Okamoto, Y. and Sekine, T. (1985) J. Biochem. (Tokyo) 98, 1143-1145
13. Spudich, J. A. and Watt, S. (1971) J. Biol. Chem. 246, 4866-4871
14. Cooper, J. A., Walker, S. B., and Pollard, T. D. (1983) J. Muscle Res. Cell Motil. 4, 253-262
15. Brune, M., Hunter, J. L., Corrie, J. E., and Webb, M. R. (1994) Biochemistry 33, 8262-8271
16. Trentham, D. R., Bardsley, R. G., Eccleston, J. F., and Weeds, A. G. (1972) Biochem. J. 126, 635-644
17. Wang, F., Kovacs, M., Hu, A., Limouze, J., Harvey, E. V., and Sellers, J. R. (2003) J. Biol. Chem. 278, 27439-27448
18. Criddle, A. H., Geeves, M. A., and Jeffries, T. (1985) Biochem. J. 232, 343-349
19. Kouyama, T. and Mihashi, K. (1981) Eur. J. Biochem. 114, 33-38
Kinetic mechanism of myosin X

20. Cremo, C. R. and Geeves, M. A. (1998) *Biochemistry* 37, 1969-1978
21. Kovacs, M., Wang, F., Hu, A., Zhang, Y., and Sellers, J. R. (2003) *J. Biol. Chem.* 278, 38132-38140
22. Furch, M., Fujita-Becker, S., Geeves, M. A., Holmes, K. C., and Manstein, D. J. (1999) *J. Mol. Biol.* 290, 797-809
23. Coluccio, L. M. and Geeves, M. A. (1999) *Biochemistry* 37, 1969-1978
24. El Mezgueldi, M., Tang, N., Rosenfeld, S. S., and Ostap, E. M. (2002) *J. Biol. Chem.* 277, 21514-21521
25. De La Cruz, E. M., Wells, A. L., Rosenfeld, S. S., Ostap, E. M., and Sweeney, H. L. (1999) *Proc. Natl. Acad. Sci. U. S. A* 96, 13726-13731
26. De La Cruz, E. M., Ostap, E. M., and Sweeney, H. L. (2001) *J. Biol. Chem.* 276, 32373-32381
27. Malnasi-Csizmadia, A., Pearson, D. S., Kovacs, M., Woolley, R. J., Geeves, M. A., and Bagshaw, C. R. (2001) *Biochemistry* 40, 12727-12737
28. White, H. D., Belknap, B., and Webb, M. R. (1997) *Biochemistry* 36, 11828-11836
29. Robblee, J. P., Olivares, A. O., and De La Cruz, E. M. (2004) *J. Biol. Chem.* 279, 38608-38617
30. Harris, D. E. and Warshaw, D. M. (1993) *J. Biol. Chem.* 268, 14764-14768
31. Trybus, K. M. and Taylor, E. W. (1982) *Biochemistry* 21, 1284-1294
32. Kovacs, M., Malnasi-Csizmadia, A., Woolley, R. J., and Bagshaw, C. R. (2002) *J. Biol. Chem.* 277, 28459-28467
33. Geeves, M. A. and Holmes, K. C. (1999) *Annu. Rev. Biochem.* 68, 687-728
34. Batra, R. and Manstein, D. J. (1999) *Biochemistry* 380, 1017-1023
35. Malnasi-Csizmadia, A., Woolley, R. J., and Bagshaw, C. R. (2000) *Biochemistry* 39, 16135-16146
36. Malnasi-Csizmadia, A., Kovacs, M., Woolley, R. J., Botchway, S. W., and Bagshaw, C. R. (2001) *J. Biol. Chem.* 276, 19483-19490
37. Park, S. and Burghardt, T. P. (2000) *Biochemistry* 39, 11732-11741
38. Yengo, C. M., Chrin, L. R., Rovner, A. S., and Berger, C. L. (2000) *J. Biol. Chem.* 275, 25481-25487
39. Sellers, J. R. (1999) *Myosins*, 2nd Edition Ed., Oxford University Press, New York
40. Sato, O., White, H. D., Inoue, A., Belknap, B., Ikebe, R., and Ikebe, M. (2004) *J. Biol. Chem.* 279, 28844-28854
41. Conibear, P. B., Bagshaw, C. R., Fajer, P. G., Kovacs, M., and Malnasi-Csizmadia, A. (2003) *Nat. Struct. Biol.* 10, 831-835
42. Coureux, P. D., Wells, A. L., Menetrey, J., Yengo, C. M., Morris, C. A., Sweeney, H. L., and Houdusse, A. (2003) *Nature* 425, 419-423
43. Holmes, K. C., Angert, I., Kull, F. J., Jahn, W., and Schroder, R. R. (2003) *Nature* 425, 423-427
44. Reubold, T. F., Eschenburg, S., Becker, A., Kull, F. J., and Manstein, D. J. (2003) *Nat. Struct. Biol.* 10, 826-830
45. Lister, I., Schmitz, S., Walker, M., Trinick, J., Buss, F., Veigel, C., and Kendrick-Jones, J. (2004) *EMBO J.* 23, 1729-1738
46. Klopfenstein, D. R. and Vale, R. D. (2004) *Mol. Biol. Cell* 15, 3729-3739
47. Baker, J. E., Kremenstova, E. B., Kennedy, G. G., Armstrong, A., Trybus, K. M., and Warshaw, D. M. (2004) *Proc. Natl. Acad. Sci. U. S. A* 101, 5542-5546
48. Rosenfeld, S. S. and Sweeney, H. L. (2004) *J. Biol. Chem.*
49. Belyantseva, I. A., Boger, E. T., and Friedman, T. B. (2003) *Proc. Natl. Acad. Sci. U. S. A* 100, 13958-13963
50. Chen, L. F., Winkler, H., Reedy, M. K., Reedy, M. C., and Taylor, K. A. (2002) *J. Struct. Biol.* 138, 92-104
**FIGURE LEGENDS**

**Figure 1: ATP binding and hydrolysis by mX-S1 in the absence of actin**

A, Tryptophan fluorescence emission spectra of 5 µM mX-S1 in the absence of nucleotide (apo) and after the addition of 300 µM ADP or 300 µM ATP. Fluorescence was excited at 295 nm with 1 nm bandwidth, and emission was detected using a bandwidth of 5 nm.

B, Observed rate constants (k\text{obs}) of single exponential fits to tryptophan fluorescence transients recorded on mixing 0.5 µM mX-S1 with different concentrations of ATP in the stopped-flow apparatus (solid circles). A hyperbolic fit of the dependence of k\text{obs} on [ATP] yielded a maximal k\text{obs} of 430 ± 80 s\(^{-1}\) with half-saturation at 310 ± 90 µM ATP. The open triangle shows the k\text{obs} of the exponential burst phase of P\text{i} production in a quenched-flow experiment where 1.7 µM mX-S1 was mixed with 50 µM ATP (k\text{obs} = 67 ± 15 s\(^{-1}\), see text). The open squares indicate the k\text{obs} values of the single exponential increase in mantATP fluorescence on mixing 0.5 µM mX-S1 with various mantATP concentrations in the stopped-flow.

C, Time course of ATP hydrolysis upon mixing 2.3 µM mX-S1 with 1 µM \(\gamma\)-\(^{32}\)P-ATP in the quenched-flow apparatus (single turnover conditions). A double exponential approximation to the reaction time profile indicated a burst phase (k\text{obs} = 2.1 s\(^{-1}\)) with a fractional amplitude \([= A_{\text{fast}}/(A_{\text{fast}} + A_{\text{slow}})]\) of 0.28, whereas the slow phase of the reaction had a k\text{obs} of 0.03 s\(^{-1}\).

Conditions: 25°C, 20 mM MOPS (pH 7.0), 5 mM MgCl\(_2\), 100 mM KCl and 0.1 mM EGTA. Error bars indicate SD for n = 3.

**Figure 2: ADP interaction of mX-S1 in the absence of actin**

A, Observed rate constants (k\text{obs}) of single exponential fits to tryptophan fluorescence transients obtained on mixing 0.4 µM mX-S1 with different concentrations of ADP in the stopped-flow. The inset shows relative amplitudes of the same reactions (fluorescence level before mix was taken as unity). A hyperbolic fit to the amplitude data yielded a maximal relative amplitude of 0.085 ± 0.002 with half-saturation at 1.0 ± 0.2 µM ADP. Note the breaks in the x axes of both panels.

B, Fractional amplitude of the slow phase \([= A_{\text{slow}}/(A_{\text{fast}} + A_{\text{slow}})]\) of the double exponential mantATP fluorescence transients on rapid mixing of 0.5 µM mX-S1 plus the indicated ADP concentrations with mantATP (in at least 5-fold molar excess over ADP) in the stopped-flow. The data were fitted to a hyperbola to yield a maximal fractional amplitude of 0.73 ± 0.02 for the slow phase with half-saturation at 1.7 ± 0.2 µM ADP. The inset shows traces for two of the data points. Trace 1 was obtained on mixing 0.5 µM mX-S1 and 2 µM ADP with 50 µM mantATP \([k_{\text{fast}} = 48 \text{ s}^{-1}(59 \text{ % amplitude}), k_{\text{slow}} = 2.8 \text{ s}^{-1}(41 \text{ %})]\). In trace 2, 0.5 µM mX-S1 and 60 µM ADP was mixed with 300 µM mantATP \([k_{\text{fast}} = 13 \text{ s}^{-1}(29 \text{ % amplitude}), k_{\text{slow}} = 1.3 \text{ s}^{-1}(71 \text{ %})]\). Pre-mixing concentrations are indicated in this panel.

C, Observed rate constants (k\text{obs}) of single exponential fits to tryptophan fluorescence transients recorded on rapidly mixing 0.7 µM mX-S1 with a premixture of 50 µM ATP plus ADP at the indicated concentrations (solid symbols). The open symbols indicate the fitted rate constants of simulated time courses obtained using the kinetic model described in the text. Traces 1, 2 and 3 of the inset are experimental tryptophan fluorescence transients of the data points at 0, 50 and 500 µM ADP, respectively (fitted rate constants are 70 s\(^{-1}\), 12 s\(^{-1}\) and 3.9 s\(^{-1}\)).

Conditions were as in Fig. 1. Error bars indicate fitting errors of k\text{obs}.

**Figure 3: Actin-activation of the mX-S1 ATPase**

Actin-activated steady-state ATPase activity of mX-S1 (50 nM) at ionic strengths of 10 mM (solid symbols) and 110 mM (open symbols). Hyperbolic fits to the datasets yielded a V\text{max} of 4.0
± 0.1 s⁻¹ and a K_ATPase of 5.7 ± 0.4 µM (I = 10 mM), and a V_max of 3.0 ± 0.3 s⁻¹ and a K_ATPase of 33 ± 5 µM (I = 110 mM).

Conditions: 25°C, 4 mM MOPS (pH 7.0), 2 mM MgCl₂, 0.1 mM EGTA, 1 mM ATP, 40 units/ml lactate dehydrogenase, 200 units/ml pyruvate kinase, 1 mM phospho-enolpyruvate, 0.2 mM NADH plus KCl to yield the stated ionic strengths. The basal ATPase activity of mX-S1 (0.03 s⁻¹) was subtracted from all data points.

**Figure 4: Strong-binding actin interaction of mX-S1**

A, Excitation and emission spectra of 1 µM pyrene-actin alone (lines marked “a”) and in the presence of 2 µM mX-S1 (“mX”) or 2 µM skeletal muscle myosin II S1 (“mII”). Excitation wavelength was 344 nm for the emission spectra, whereas the excitation spectra were recorded at an emission wavelength of 406 nm. Bandwidths were 1 and 5 nm for the excitation and emission sides, respectively. Data were normalized to the 344 nm excitation and 406 nm emission peaks of pyrene-actin alone.

B, Pyrene fluorescence titration of 30 nM pyrene-actin with increasing concentrations of mX-S1. Excitation was at 344 nm (1 nm bandwidth) and emission was detected at 406 nm (5 nm bandwidth). Data were normalized to the fluorescence intensity of pyrene-actin alone. A hyperbolic fit to the dataset yielded a K_A of 0.19 ± 0.03 µM with a final fluorescence level of 0.84 ± 0.02. The inset shows the results of a stopped-flow titration where 50 nM pyrene-actin was pre-incubated with the indicated mX-S1 concentrations and then rapidly mixed with 10 µM ATP to fully dissociate acto-S1 (pre-mixing concentrations indicated). The [mX-S1]-dependence of the relative amplitudes (expressed as ΔF/F_final) of the recorded single-exponential pyrene fluorescence transients (k_obs = 4.3 ± 0.5 s⁻¹) was fitted to a quadratic binding equation to yield a K_A of 0.09 ± 0.04 µM and a maximal ΔF/F_final value of 0.09 ± 0.005.

C, Observed rate constants (k_obs) of pyrene fluorescence decrease transients recorded on mixing 0.1–0.3 µM mX-S1 with various concentrations of pyrene-actin in the absence (solid symbols) and presence (open symbols) of 1 mM ADP (in all syringes). Linear fits to the datasets yielded slopes of 2.2 ± 0.02 µM⁻¹s⁻¹ (k_A) and 0.26 ± 0.02 µM⁻¹s⁻¹ (k_A0) for mX-S1 and mX-S1.ADP binding to pyrene-actin, respectively. The y intercepts indicating the dissociation rate constant from pyrene-actin were 0.41 ± 0.06 s⁻¹ (k_A) and 0.81 ± 0.04 s⁻¹ (k_D_A) for mX-S1 and mX-S1.ADP, respectively. The inset shows traces of 0.3 µM mX-S1 binding to 5 µM pyrene-actin in the absence (trace 1, k_obs = 11 s⁻¹) and presence of 1 mM ADP (trace 2, k_obs = 2.0 s⁻¹).

D, Pyrene fluorescence transient recorded on rapid mixing of a pre-mixture of 0.2 µM pyrene-actin and 0.3 µM mX-S1 with 10 µM unlabeled actin in the absence of nucleotide. A single exponential fit of the transient gave a k_obs of 0.36 s⁻¹ for mX-S1 dissociation from pyrene-actin (k_A) in the experiment shown.

Conditions were as in Fig. 1. Data points shown in panels B and C are averages of 3 experiments.

**Figure 5: ATP-induced dissociation of acto-mX-S1, ATP hydrolysis and weak actin binding**

A, Observed rate constants (k_obs) of ATP-induced pyrene-acto-mX-S1 dissociation on rapid mixing of a pre-mixture of 0.25 µM mX-S1 and 0.15 µM pyrene-actin with the indicated ATP concentrations in the stopped-flow. The recorded transients were fitted to single exponentials. The solid circles show k_obs values of pyrene fluorescence records (I = 35 mM), whereas the open circles indicate k_obs values of light scattering transients of the same reactions. Hyperbolic fits yielded maximal k_obs values of 620 ± 50 and 630 ± 40 s⁻¹ (k'_2 in Scheme 3) with half-saturation (K'_1) at 290 ± 50 and 240 ± 40 µM ATP for pyrene fluorescence and light scattering, respectively. The solid squares show pyrene fluorescence k_obs values for the same reactions at I = 125 mM. The inset shows light scattering (trace 1, k_obs = 60 s⁻¹) and pyrene fluorescence (trace 2, k_obs = 66 s⁻¹) traces recorded at 40 µM ATP (I = 35 mM).
B. Time courses of ATP hydrolysis on mixing 1.4 µM mX-S1 and 9 µM actin with 50 µM (solid symbols) and 10 µM (open symbols) γ-32P-ATP in the quenched-flow apparatus. Data were fitted to a single exponential burst with a linear steady-state phase. The k<sub>obs</sub> values of the burst phase were 98 s<sup>-1</sup> (50 µM ATP) and 14 s<sup>-1</sup> (10 µM ATP), whereas the burst amplitudes were 0.33 µM (corresponding to 0.24 mol P<sub>i</sub>/mol mX-S1) in 50 µM ATP and 0.35 µM (0.25 mol P<sub>i</sub>/mol mX-S1) in 10 µM ATP. The slope of the linear steady-state phase was fairly uncertain, but its value was in the range expected based on the steady-state ATPase measurements shown in Fig. 3 (0.2–0.5 s<sup>-1</sup>). Error bars in the graph indicate SD for n = 4.

C. Actin binding of mX-S1 in the presence of ATP and/or ADP as monitored by acto-mX-S1 cosedimentation. 2 µM mX-S1 was mixed with the indicated actin concentrations and 1 mM ATP (solid circles, I = 125 mM; open circles, I = 45 mM), a mixture of 1 mM ATP and 100 µM ADP (open squares, I = 125 mM) or 200 µM ADP alone (solid squares, I = 125 mM). After ultracentrifugation, the amount of mX-S1 heavy chain in the supernatants and pellets was analyzed by densitometry of SDS-PAGE bands. Error bars represent SD for n = 2. The inset shows mX-S1 heavy chain (2 µM) SDS-PAGE bands of representative samples at I = 125 mM (S = supernatant, P = pellet). Row 1, control in the absence of actin; row 2, 20 µM actin and 1 mM ATP; row 3, 20 µM actin, 1 mM ATP and 100 µM ADP; row 4, 20 µM actin and 1 mM ADP. To remove potential ADP contamination, 200 units/ml pyruvate kinase and 1 mM phospho-enolpyruvate were added to the samples in which only ATP and no ADP was included.

Conditions were as in Fig. 1 except that in panels A and C ionic strengths were as indicated.

Figure 6: Phosphate release from acto-mX-S1

A. MDCC-PBP fluorescence transients recorded in double-mixing stopped-flow experiments at I = 45 mM. 2.3 µM mX-S1 was first mixed with 1.1 µM ATP (concentrations after the first mix), incubated for 1 s for ATP binding and hydrolysis to occur, and then rapidly mixed with increasing concentrations of actin (actin concentrations after the second mix are indicated; data acquisition started at the second mix). At 8 µM actin, a single exponential transient was observed with a k<sub>obs</sub> of 1.4 s<sup>-1</sup> (trace 1). At 50 µM actin (trace 2), the transient was double exponential with k<sub>obs</sub> values of 25 s<sup>-1</sup> (35 % fractional amplitude) and 1.0 s<sup>-1</sup> (65 %). Traces were normalized to a total amplitude of 1.

B. Dependence of the k<sub>obs</sub> values of the fast (solid symbols) and slow (open symbols) phases on actin concentration in P<sub>i</sub> release experiments described in panel A. A hyperbolic fit to the fast phase k<sub>obs</sub> values indicated a maximal k<sub>obs</sub> (k<sub>4'</sub> in Scheme 3) of 90 ± 30 s<sup>-1</sup> with half-saturation at 130 ± 50 µM actin (K<sub>DP</sub>). A linear fit to the same dataset (not shown) yielded an apparent second order rate constant of actin binding to the mX-S1.ADP.P<sub>i</sub> complex of 0.56 ± 0.03 µM<sup>-1</sup>s<sup>-1</sup> (k<sub>4'/KDP</sub>). Conditions were as in Fig. 1 except that ionic strengths were as indicated.

C. Observed rate constants (k<sub>obs</sub>) of single exponential P<sub>i</sub> release transients recorded in double-mixing stopped-flow experiments similar to those of panel A but at I = 125 mM. A linear fit to the dependence of k<sub>obs</sub> on actin concentration yielded 0.019 ± 0.002 µM<sup>-1</sup>s<sup>-1</sup> for k<sub>4'/KDP</sub>. The y intercept of the fit was 0.03 ± 0.01 s<sup>-1</sup>, in line with the basal mX-S1 ATPase activity (Table 1). The inset shows an MDCC-PBP fluorescence trace recorded at 5 µM actin that had a k<sub>obs</sub> of 0.13 s<sup>-1</sup>. 4 µM MDCC-PBP was present in all syringes. Conditions were as in Fig. 1 except that ionic strengths were as indicated. Error bars indicate SD for n = 3.

Figure 7: ADP kinetics of acto-mX-S1

A. Observed rate constants (k<sub>obs</sub>) of pyrene fluorescence increase transients recorded on mixing a pre-mixture of 0.25 µM mX-S1, 0.2 µM pyrene-actin and the indicated ADP concentrations with 300 µM ATP in the stopped-flow. The inset shows k<sub>obs</sub> values of pyrene fluorescence transients recorded on rapid mixing of 0.2 µM mX-S1 plus 0.15 µM pyrene-actin.
Kinetic mechanism of myosin X

with a mixture of 200 µM ATP and the indicated ADP concentrations. Note the breaks in the x axes of both panels. In panels A and B, solid symbols show the fitted rate constants of the experimental traces, whereas open symbols indicate the rate constants resulting from kinetic simulations based on the model described in the text.

B, Observed rate constants (k_{obs}) of pyrene fluorescence transients on rapid mixing of a pre-mixture of 0.2 µM mX-S1, 0.15 µM pyrene-actin and 50 µM ADP with the indicated ATP concentrations in the stopped-flow. A hyperbolic fit to the dataset yielded a maximal k_{obs} (= k_{AD}, Schemes 3 and 4) of 17.6 s^{-1}. The inset shows a trace obtained at 200 µM ATP that had a k_{obs} of 9.8 s^{-1}.

C, Dependence of the observed rate constants (k_{obs}) of mantATP fluorescence transients recorded on rapidly mixing a premixture of 1 µM mX-S1, 12 µM actin and 30 µM ADP with increasing mantATP concentrations in the stopped-flow. Data were fitted to a hyperbola to obtain a maximal k_{obs} (= k_{AD}) of 18.8 s^{-1}. The inset shows a transient recorded at 100 µM mantATP (k_{obs} = 15 s^{-1}).

Conditions were as in Fig. 1. Pre-mixing concentrations are stated throughout this figure. All traces were fitted to single exponentials (see text).

Figure 8: Simulated duty ratio, actin attachment and steady-state acto-mX-S1 ATPase activity

Results of computational kinetic simulations of the dependence of steady-state properties of mX-S1 on actin concentration are shown. The experimentally determined kinetic constants (Tables 1 and 4) were fed into a kinetic model of the entire mX-S1/acto-mX-S1 ATPase cycle according to Schemes 1 and 3. Additional parameters used were: K_T = 43 µM (rapid equilibrium), K_{DP} = 130 µM (rapid equilibrium), k_3 = 30 s^{-1}, k_3' = 100 s^{-1}, k_3'' = 0.1 s^{-1}, k_3''' = 1 s^{-1}, k_4' = 90 s^{-1} (irreversible step), [ATP] = 1 mM, [ADP] = 0. The duty ratio (i.e. the sum of the fractional abundances of the strongly actin-bound states (AM and AMD in Scheme 3), shown in triangles, left y axis) acquired a maximal value of 0.16 at around 100 µM actin. The fractional actin attachment (i.e. the sum of the fractional abundances of all (weak and strong) actin-attached states, circles, left y axis) converged to 1 and showed half-saturation around 25 µM actin. The steady-state ATPase activity (squares, right y axis) exhibited a maximal value around 3 s^{-1} at 100 µM actin (with half-saturation around 15 µM actin), and then declined to ~1 s^{-1} at high actin concentrations.

Figure 9: Amino acid sequence comparison of the actin binding interface of myosins II and X

The upper panel shows amino acid sequence alignments of rabbit skeletal muscle myosin II, human non-muscle myosin IIIB and bovine myosin X for four major structural elements of the actin-binding interface. Positions that are occupied by residues of similar chemical character in the two myosin II isoforms but by a very different one in myosin X are highlighted in yellow. The green color marks positions in which myosin X shows identity with at least one of the myosin II isoforms. Loop 2 residues with positively or negatively charged side chains are marked with blue and red, respectively. The lower panel highlights the residues marked yellow and green in the context of the structural model of the rigor actomyosin II complex (50). The myosin II heavy chain head fragment is colored gray (light chains are omitted for clarity). Actin monomers are shown in different shades of magenta. The actin residue R372 of the relevant monomer (the closest ‘visible’ one to C374 labeled with the pyrene fluorophore in pyrene-actin) is highlighted in red.

Figure was prepared using ClustalW (upper panel) and WebLabViewerPro 4.0 (lower panel).
Kinetic mechanism of myosin X

\[
\begin{array}{cccccc}
K_D & K_1 & k_2 & K_3 & k_4 & K_5 & K_6 \\
M \leftrightarrow MT \rightarrow M^*T \leftrightarrow M^{**}DP \rightarrow M^*D \leftrightarrow MD \leftrightarrow M
\end{array}
\]

Scheme 1

\[
\begin{align*}
K_D \\
M \leftrightarrow MD \\
K_A & \uparrow \downarrow K_{DA} \\
AM \leftrightarrow AMD \\
K_{AD}
\end{align*}
\]

Scheme 2

\[
\begin{align*}
K_1' & \quad k_2' & \quad K_3' & \quad k_4' & \quad K_{AD} \\
AM \leftrightarrow AMT \rightarrow AMT \leftrightarrow AMDP \rightarrow AMD \leftrightarrow AM \\
K_T & \uparrow \downarrow K_{DP} \\
MT \leftrightarrow MDP \\
K_3
\end{align*}
\]

Scheme 3

\[
\begin{align*}
k_2'/K_1' \\
AM + T \rightarrow A + MT
\end{align*}
\]

\[
\begin{align*}
K_{AD} \\
AM + D \leftrightarrow AMD
\end{align*}
\]

Scheme 4

\textsuperscript{a}Equilibrium constants are expressed as dissociation constants, or for first-order transitions in a left-to-right direction in all schemes. Arrows for associating or dissociating components are omitted for clarity in all schemes except Scheme 4. Asterisks indicate states with elevated tryptophan fluorescence. Abbreviations used in schemes: A, actin; M, myosin; T, ATP; D, ADP; P, phosphate.

\textsuperscript{b}Strong-binding acto-mX-S1 states are underlined.
Table 1: Kinetic parameters of the basal ATPase cycle of mX-S1

| Parameter | Value (mM) | Unit | Description |
|-----------|------------|------|-------------|
| \(k_2/k_1\) (\(\mu M^{-1}s^{-1}\)) (mantATP) | 1.1 ± 0.1 | \(\mu M^{-1}s^{-1}\) |  |
| \(k_2/k_1\) (\(\mu M^{-1}s^{-1}\)) (tryptophan) | 1.1 ± 0.1 | \(\mu M^{-1}s^{-1}\) |  |
| \(k_2\) (s\(^{-1}\)) (tryptophan) | > 250 | s\(^{-1}\) |  |
| \(K_2\) (quenched-flow) | 0.3 ± 0.1 | |  |
| \(k_3 + k_{-3}\) (s\(^{-1}\)) (quenched-flow, tryptophan) | > 80 | s\(^{-1}\) |  |
| \(k_{obsp,Pi}\) (s\(^{-1}\)) (quenched-flow, MDCC-PBP) | 0.03 ± 0.01 | s\(^{-1}\) |  |
| \(k_4\) (s\(^{-1}\)) (calculated as \(k_{obsp,Pi}(I+K_3/K_3)\)) | 0.13 | s\(^{-1}\) |  |
| \(K_5\) (ADP chasing with mantATP) | 0.37 ± 0.03 | |  |
| \(k_5\) (s\(^{-1}\)) (tryptophan, ADP chasing with mantATP) | 1.1–1.3 | s\(^{-1}\) |  |
| \(k_6\) (s\(^{-1}\)) (tryptophan, ADP chasing with mantATP) | 3.1 | s\(^{-1}\) |  |
| \(K_6\) (\(\mu M\)) (calculated as \(K_D(I+K_3/K_3)\)) | 3.7–6.3 | \(\mu M\) |  |
| \(k_6\) (s\(^{-1}\)) (tryptophan, ADP chasing with mantATP) | 13–16 | s\(^{-1}\) |  |
| \(k_{-6}\) (s\(^{-1}\)) (calculated as \(k_6/K_6\)) | 2.1–4.3 | s\(^{-1}\) |  |
| \(K_D\) (\(\mu M\)) (ADP chasing with mantATP, amplitudes) | 1.7 ± 0.2 | \(\mu M\) |  |
| \(K_D\) (\(\mu M\)) (tryptophan, amplitudes) | 1.0 ± 0.2 | \(\mu M\) |  |
| steady-state ATPase \(k_{cat}\) (s\(^{-1}\)) (NADH-linked assay) | 0.03 ± 0.01 | s\(^{-1}\) |  |

\(^{\text{a}}\)Conditions: 25°C, 20 mM MOPS (pH 7.0), 5 mM MgCl\(_2\), 100 mM KCl, 0.1 mM EGTA. Means ± SD for \(n = 3\) are reported. Numbering of steps refers to Scheme 1.

Table 2: Actin-activated steady-state ATPase parameters of mX-S1

| I (mM) | \(V_{max}\) (s\(^{-1}\)) | \(K_{ATPase}\) (\(\mu M\)) |
|--------|-----------------|-----------------|
| 10     | 4.0 ± 1.5       | 5.1 ± 0.6       |
| 30     | 5.3 ± 0.3       | 7.3 ± 1.0       |
| 60     | 5.3 ± 2.1       | 36 ± 8          |
| 110    | 3.0 ± 1.0       | 33 ± 5          |

\(^{\text{a}}\)Conditions: 25°C, 2 mM MOPS (pH 7.0), 2 mM MgCl\(_2\), 0.1 mM EGTA, 1 mM ATP plus KCl to yield the stated ionic strengths. Means ± SD for \(n = 3\) are reported.
**Table 3: Fluorescent properties of pyrene-acto-S1 complexes**

|                          | Pyrene-actin | Pyrene-myosin X S1 | Pyrene-acto-skeletal muscle myosin II S1 | Pyrene-acto-non-muscle myosin IIB S1 |
|--------------------------|--------------|--------------------|------------------------------------------|--------------------------------------|
| Relative fluorescence intensity (excitation at 365 nm) | 1.00 | 0.68 ± 0.05 | 0.26 ± 0.04 | 0.25 ± 0.04 |
| Fluorescence anisotropy  | 0.26 ± 0.02  | 0.24 ± 0.02 | 0.20 ± 0.02 | 0.20 ± 0.02 |
| Stern-Volmer quenching constant (acrylamide) (M⁻¹)   | 5.4 ± 0.2    | 2.0 ± 0.3     | 0.5 ± 0.2   | 1.2 ± 0.2   |

*aConditions: 25°C, 20 mM MOPS (pH 7.0), 5 mM MgCl₂, 100 mM KCl, 0.1 mM EGTA. Means ± SD for n = 3 are reported.

**Table 4: Transient kinetic parameters of acto-mX-S1**

| Parameter                                      | Value                      |
|-----------------------------------------------|----------------------------|
| \(k_2'/K_1'\) (\(\mu\text{M}^{-1}\text{s}^{-1}\)) (pyrene-actin) | 0.55 ± 0.04                |
| \(k_2'/K_1'\) (\(\mu\text{M}^{-1}\text{s}^{-1}\)) (\(I = 35\text{ mM}\); pyrene-actin, light scattering) | 1.8 ± 0.2                  |
| \(K_1'\) (\(\mu\text{M}\)) (\(I = 35\text{ mM}\); pyrene-actin, light scattering) | 260 ± 30                   |
| \(k_2'\) (\(s^{-1}\)) (\(I = 35\text{ mM}\); pyrene-actin, light scattering) | 630 ± 50                   |
| \(K_T\) (\(\mu\text{M}\)) (\(I = 45\text{ mM}\); numerical analysis) | ~ 40                       |
| \(K_{DP}\) (\(\mu\text{M}\)) (\(I = 45\text{ mM}\); MDCC-PBP) | 130 ± 50                   |
| \(K_{DP}\) (\(\mu\text{M}\)) (MDCC-PBP) | > 100                      |
| \(K_3'\) (\(I = 43\text{ mM}\); calculated as \(K_2'K_T/K_{DP}\)) | ~ 0.1                      |
| \(k_3' + k_{-3'}\) (\(s^{-1}\)) (\(I = 45\text{ mM}\); MDCC-PBP) | 0.88 ± 0.11                |
| \(k_4'\) (\(s^{-1}\)) (MDCC-PBP) | 90 ± 30                    |
| \(k_4'/K_{DP}\) (\(\mu\text{M}^{-1}\text{s}^{-1}\)) (\(I = 45\text{ mM}\); MDCC-PBP) | 0.56 ± 0.03                |
| \(k_4'/K_{DP}\) (\(\mu\text{M}^{-1}\text{s}^{-1}\)) (MDCC-PBP) | 0.019 ± 0.002              |
| \(k_{AD}\) (\(s^{-1}\)) (pyrene-actin; ADP chasing with mantATP) | 18 ± 1                     |
| \(k_{AD}\) (\(\mu\text{M}^{-1}\text{s}^{-1}\)) (numerical analysis) | 2.1                        |
| \(K_{AD}\) (\(\mu\text{M}\)) (calculated as \(k_{AD}/k_{-AD}\)) | 8.4                        |
| \(k_{-A}\) (\(\mu\text{M}^{-1}\text{s}^{-1}\)) (pyrene-actin) | 2.1 ± 0.2                  |
| \(k_A\) (\(s^{-1}\)) (pyrene-actin) | 0.41 ± 0.10                |
| \(K_A\) (\(\mu\text{M}\)) (calculated as \(k_A/k_{-A}\)) | 0.20                       |
| \(K_A\) (\(\mu\text{M}\)) (pyrene-actin titrations) | 0.14 ± 0.05                |
| \(k_{DA}\) (\(\mu\text{M}^{-1}\text{s}^{-1}\)) (pyrene-actin) | 0.26 ± 0.02                |
| \(k_{DA}\) (\(s^{-1}\)) (pyrene-actin) | 0.34 ± 0.03                |
| \(K_{DA}\) (\(\mu\text{M}\)) (calculated as \(k_{DA}/k_{-DA}\)) | 1.3                        |
| \(K_{DA}\) (\(\mu\text{M}\)) (pyrene-actin titrations) | 1.0 ± 0.3                  |
| \(K_{AD}/K_D\) | 6.2                      |
| \(K_{DA}/K_A\) | 6.8                      |

*aConditions: 25°C, 20 mM MOPS (pH 7.0), 5 mM MgCl₂, 100 mM KCl, 0.1 mM EGTA (\(I = 125\text{ mM}\)) if not otherwise indicated. Means ± SD for n = 3 are reported. Numbering of steps refers to Scheme 3.
Kinetic mechanism of myosin X

Figure 1

A

Fluorescence (AU)

Wavelength (nm)

ATP
ADP
apo

B

$k_{obs}$ (s$^{-1}$)

[ATP] or [mantATP] (µM)

C

Fractional ATP hydrolysis

Time (s)

Fractional ATP hydrolysis

Time (s)
Figure 2

(A) $k_{obs}$ (s$^{-1}$) vs. [ADP] (µM)

(B) Fractional amplitude of slow phase vs. [ADP] (µM)

(C) $k_{on}$ (s$^{-1}$) vs. [ADP] (µM)
Figure 3

Steady-state ATPase activity (s⁻¹) vs [actin] (µM)

Figure 4

A

Fluorescence (AU) vs Wavelength (nm)

B

Fluorescence (AU) vs mX-S1 (µM)

C

kₚ₅₀ (s⁻¹) vs [pyrene-actin] (µM)

D

Fluorescence (AU) vs Time (s)
Kinetic mechanism of myosin X

Figure 5

A

![Graph A](image)

B

![Graph B](image)

C

![Graph C](image)
Figure 6

A

Fluorescence (AU)

Time (s)

B

\[ \frac{A_{fast}}{A_{fast} + A_{slow}} \]

[actin] (µM)

k_{obs} (s^{-1})

[actin] (µM)

C

Fluorescence (AU)

Time (s)

k_{off} (s^{-1})

[actin] (µM)
Figure 7
Figure 8

Fractional attachment vs. [actin] (µM) and ATPase activity (s⁻¹)

Kinetic mechanism of myosin X
Kinetic mechanism of myosin X

Figure 9

cardiomyopathy loop (HCM)
- skeletal II: YPRVKECNLYVTK
- non-muscle IIB: TPRIKVGRXVQK
- myosin X: CRSMFLRGEILT

helix-turn-helix motif (HTH)
- skeletal II: KPMG---IFSILEEECMFPKATDTSDKMKNLYEQR
- non-muscle IIB: RPANPPGVLALLDEECWFPKATDKLVTEKLVQQE
- myosin X: KKLN---LALINESHFLOATDSILEKLNQH

loop 3
- skeletal II: QKRPKAKEKVE
- non-muscle IIB: QKPRQLKDAD
- myosin X: VKPRAVANNF

loop 2 and loop 2 helix
- skeletal II: TA--------ALAE---GGKKGKGGKSSFQVSALFRENN
- non-muscle IIB: VRIKVGLKVTGMIATAFSGAYKTKG-MFRPVGQLYKSLT
- myosin X: VS--------SNNNRTLKCSKHRR---PFVSSFKDSLH
Mechanism of action of myosin X, a membrane-associated molecular motor
Mihaly Kovacs, Fei Wang and James R. Sellers

J. Biol. Chem. published online February 10, 2005

Access the most updated version of this article at doi: 10.1074/jbc.M500616200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts